Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma-Reference-Cited by-同舟云学术

Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma

Published:2017-11-10 Issue:18 Volume:77 Page:2013-2024
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Blair Hannah A.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/article/10.1007/s40265-017-0837-7/fulltext.html

Reference51 articles.

1. Kumar SK, Callander NS, Alsina M, et al. Multiple myeloma, version 3.2017: NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15(2):230–69.

2. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26(1):149–57.

3. Usmani S, Ahmadi T, Ng Y, et al. Analysis of real-world data on overall survival in multiple myeloma patients with ≥3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD. Oncologist. 2016;02(21):1355–61.

4. Lonial S, Durie B, Palumbo A, et al. Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives. Leukemia. 2016;30(3):526–35.

5. Janssen Biotech Inc. Darzalex (daratumumab) injection, for intravenous use: US prescribing information. 2016. http://www.janssenmd.com . Accessed 25 Oct 2017.

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An up-conversion fluorescence lateral-flow immunoassay for rapid detection of Daratumumab in serum protein electrophoresis clinical samples;Clinica Chimica Acta;2024-06

2. Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant;Cochrane Database of Systematic Reviews;2024-05-02

3. Clinical outcomes of pomalidomide‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in China;Cancer Medicine;2024-05

4. Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma;Cost Effectiveness and Resource Allocation;2024-02-28

5. Safety of daratumumab in the real-world: a pharmacovigilance study based on FAERS database;Expert Opinion on Drug Safety;2023-12-18